Tumorigenesis mechanism and application strategy of the MDCK cell line: A systematic review

IF 1.5 4区生物学 Q4 BIOCHEMICAL RESEARCH METHODS

Biologicals Pub Date : 2023-08-01 DOI:10.1016/j.biologicals.2023.101699

Di Yang , Lingwei Huang , Jiamin Wang , Huihao Wu , Zhenbin Liu , Ayimuguli Abudureyimu , Zilin Qiao

{"title":"Tumorigenesis mechanism and application strategy of the MDCK cell line: A systematic review","authors":"Di Yang , Lingwei Huang , Jiamin Wang , Huihao Wu , Zhenbin Liu , Ayimuguli Abudureyimu , Zilin Qiao","doi":"10.1016/j.biologicals.2023.101699","DOIUrl":null,"url":null,"abstract":"<div>Influenza is an acute respiratory infectious disease caused by influenza virus that seriously endangers people's health. Influenza vaccination is the most effective means to prevent influenza virus infection and its serious complications. MDCK cells are considered to be superior to chicken embryos for the production of influenza vaccines, but the tumorigenicity of cells is a concern over the theoretical possibility of the risk of adverse events. The theoretical risks need to be adequately addressed if public confidence in programs of immunization are to be maintained. In this paper, studies of the tumorigenic potential of cell lines, with MDCK cells as an example, published since 2010 are reviewed. The mechanism of tumorigenicity of MDCK cells is discussed with reference to cell heterogeneity and epithelial to mesenchymal transition (EMT). Understanding the mechanism of the acquisition of a tumorigenic phenotype by MDCK cells might assist in estimating potential risks associated with using tumorigenic cell substrates for vaccine production.</div>","PeriodicalId":55369,"journal":{"name":"Biologicals","volume":"83 ","pages":"Article 101699"},"PeriodicalIF":1.5000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologicals","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1045105623000374","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Influenza is an acute respiratory infectious disease caused by influenza virus that seriously endangers people's health. Influenza vaccination is the most effective means to prevent influenza virus infection and its serious complications. MDCK cells are considered to be superior to chicken embryos for the production of influenza vaccines, but the tumorigenicity of cells is a concern over the theoretical possibility of the risk of adverse events. The theoretical risks need to be adequately addressed if public confidence in programs of immunization are to be maintained. In this paper, studies of the tumorigenic potential of cell lines, with MDCK cells as an example, published since 2010 are reviewed. The mechanism of tumorigenicity of MDCK cells is discussed with reference to cell heterogeneity and epithelial to mesenchymal transition (EMT). Understanding the mechanism of the acquisition of a tumorigenic phenotype by MDCK cells might assist in estimating potential risks associated with using tumorigenic cell substrates for vaccine production.

查看原文本刊更多论文

MDCK细胞系的肿瘤发生机制及应用策略综述

流感是由流感病毒引起的严重危害人体健康的急性呼吸道传染病。接种流感疫苗是预防流感病毒感染及其严重并发症的最有效手段。MDCK细胞被认为在生产流感疫苗方面优于鸡胚，但细胞的致瘤性令人担忧的是不良事件风险的理论可能性。如果要保持公众对免疫计划的信心，就需要充分解决理论风险。本文综述了自2010年以来发表的以MDCK细胞为例的细胞系致瘤潜力的研究。结合细胞异质性和上皮-间充质转化（EMT），探讨了MDCK细胞致瘤性的机制。了解MDCK细胞获得致瘤表型的机制可能有助于估计使用致瘤细胞底物生产疫苗的潜在风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biologicals 生物-生化研究方法

CiteScore

3.70

自引率

0.00%

发文量

审稿时长

48 days

期刊介绍： Biologicals provides a modern and multidisciplinary international forum for news, debate, and original research on all aspects of biologicals used in human and veterinary medicine. The journal publishes original papers, reviews, and letters relevant to the development, production, quality control, and standardization of biological derived from both novel and established biotechnologies. Special issues are produced to reflect topics of particular international interest and concern.Three types of papers are welcome: original research reports, short papers, and review articles. The journal will also publish comments and letters to the editor, book reviews, meeting reports and information on regulatory issues.